Light Chain Amyloidosis (AL Amyloidosis)

Light Chain Amyloidosis, also known as AL Amyloidosis, is the most common type of systemic amyloidosis. It arises when a small clone of abnormal plasma cells in the bone marrow produces excess immunoglobulin light chains — most often lambda type — that misfold and aggregate into insoluble amyloid fibrils. These fibrils deposit progressively in the extracellular matrix of vital organs, disrupting their architecture and function.

The heart and kidneys are the most frequently and severely affected organs. Cardiac amyloidosis — characterised by restrictive cardiomyopathy, preserved ejection fraction, and progressive heart failure — is the single most important determinant of outcomes in AL amyloidosis. Renal involvement presents with heavy proteinuria and nephrotic syndrome. Peripheral and autonomic neuropathy, hepatomegaly, soft tissue infiltration (macroglossia, periorbital purpura), and coagulation factor X deficiency are also recognised manifestations.

AL amyloidosis is frequently underdiagnosed or misattributed to more common cardiac or renal conditions. The median time from symptom onset to diagnosis has historically exceeded one year, during which organ damage accumulates. Prompt biomarker assessment — including NT-proBNP, cardiac troponins, and serum free light chains — combined with bone marrow biopsy and tissue biopsy showing apple-green birefringence on Congo red staining, remain the diagnostic cornerstones.

Treatment is directed at eliminating the underlying plasma cell clone using bortezomib-based combinations, with or without autologous stem cell transplantation (ASCT) in eligible patients. Daratumumab-based regimens have demonstrated substantial improvement in haematologic response depth, and combinations such as daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) are now a standard of care in newly diagnosed AL amyloidosis.

AL amyloidosis is classified primarily by the dominant organ system affected, which determines clinical presentation and informs prognosis and treatment urgency. Most patients have multi-organ involvement at the time of diagnosis, though one organ typically dominates the clinical picture.

AL amyloidosis presents with diverse and non-specific symptoms that reflect the distribution of amyloid deposition across multiple organ systems. The insidious onset and overlap with common conditions such as heart failure, nephrotic syndrome, and peripheral neuropathy frequently contribute to diagnostic delay. Clinicians should maintain a high index of suspicion in middle-aged to older adults presenting with multi-system involvement.

AL amyloidosis arises from an abnormal clone of plasma cells in the bone marrow that secretes immunoglobulin light chains in excess. These light chains have an intrinsic propensity to misfold — due to their specific amino acid sequence characteristics — and self-assemble into beta-sheet-rich amyloid fibrils. The triggers for this underlying clonal plasma cell disorder are not fully understood but mirror risk factors for plasma cell neoplasms generally.

The diagnosis of AL amyloidosis requires a combination of clinical suspicion, laboratory assessment, tissue biopsy demonstrating amyloid deposits, and typing to confirm that the amyloid is composed of immunoglobulin light chains. Accurate organ staging using cardiac biomarkers is essential to guide treatment selection. The diagnostic workup typically involves several specialist teams including haematology, cardiology, nephrology, and pathology.

AL amyloidosis is staged using biomarker-based systems rather than TNM staging. The Mayo Clinic 2004 staging system and its revised 2012 version (incorporating dFLC) are the most widely used internationally. These systems stratify patients by cardiac risk — which is the primary driver of mortality — and inform decisions about treatment intensity and eligibility for autologous stem cell transplantation.

Treatment of AL amyloidosis aims to eliminate or deeply suppress the underlying plasma cell clone — halting production of the amyloidogenic light chains — thereby allowing gradual organ stabilisation and, in some cases, partial or complete organ recovery. The depth of haematologic response (particularly a very good partial response or complete response) strongly correlates with the likelihood of organ response. Treatment choice is guided by disease stage, organ function, performance status, and eligibility for ASCT.

The landscape of AL amyloidosis therapy has transformed substantially over the past decade, with the introduction of anti-CD38 monoclonal antibodies, proteasome inhibitors, and next-generation agents. Several novel approaches targeting amyloid fibril deposits directly — rather than the plasma cell clone — are in late-stage development and represent a fundamentally different therapeutic strategy. CancerFax helps patients access specialist centres in India and China where novel regimens and clinical trials are available.

Biomarker assessment is central to diagnosis, staging, treatment selection, and response monitoring in AL amyloidosis. Serial measurement of haematologic and organ biomarkers guides clinicians in assessing whether clone suppression is adequate and whether organ responses are occurring. FISH cytogenetics on plasma cells increasingly informs therapy selection.

AL amyloidosis is a complex, rare disorder where management at a specialist amyloidosis centre — or at minimum with input from an experienced haematologist — substantially influences outcomes. The diagnosis is frequently delayed or missed, and treatment decisions require careful integration of haematologic staging, organ assessment, cytogenetics, and eligibility for ASCT. In several clinical scenarios below, a second specialist opinion is strongly advisable.

Prognosis in AL amyloidosis is primarily determined by the degree of cardiac involvement at the time of diagnosis, the depth of haematologic response achieved with treatment, and the extent to which organ stabilisation and recovery occur. The introduction of daratumumab-based regimens has meaningfully shifted the distribution of haematologic responses towards deeper remissions, with corresponding improvements in organ outcomes and event-free survival. Cardiac AL amyloidosis at Stage IV continues to carry the most challenging prognosis, underscoring the importance of early diagnosis and rapid treatment initiation.

Living with AL amyloidosis requires attention to organ-specific supportive measures alongside the disease-directed treatment. A multidisciplinary team — typically including haematology, cardiology, nephrology, and palliative care where appropriate — provides coordinated supportive management throughout the treatment journey. Several important principles guide supportive care in this condition.